Zurich Cantonal Bank
NTLA icon

Zurich Cantonal Bank’s Intellia Therapeutics NTLA Stock Holding History

Zurich Cantonal Bank’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-63,178
Closed -$568K – 3181
2025
Q4 		$568K Buy
+63,178
New +$870K ﹤0.01% 1715

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Zurich Cantonal Bank's NTLA Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 69,324 shares worth $889K. The stake represents ﹤0.01% of the portfolio and ranks #1497 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in NTLA as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in NTLA in Q4 2017 and has held it in 33 quarters since. The position peaked at $2.08M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Zurich Cantonal Bank held 69,324 shares of Intellia Therapeutics worth $889K as of Q1 2026.
  • Intellia Therapeutics was a new Zurich Cantonal Bank position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1497 holding.
  • Zurich Cantonal Bank first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 33 quarters since.
  • Zurich Cantonal Bank's Intellia Therapeutics position peaked at $2.08M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.